NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024

Chrysalyne D. Schmults(Merck Institute for Science Education), Rachel Blitzblau(Cancer Institute (WIA)), Sumaira Z. Aasi(Cancer Institute (WIA)), Murad Alam(Merck Institute for Science Education), Arya Amini(City Of Hope National Medical Center), Kristin Bibee(Merck Institute for Science Education), Diana Bolotin(Merck Institute for Science Education), Jeremy S. Bordeaux(Cleveland Clinic), Pei-Ling Chen(Moffitt Cancer Center), Carlo M. Contreras(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Dominick J. DiMaio(Susan Thompson Buffett Foundation), Jessica M. Donigan(University of Utah), Jeffrey M. Farma(Fox Chase Cancer Center), Karthik Ghosh(WinnMed), Kelly L. Harms(Merck Institute for Science Education), Alan L. Ho(Memorial Sloan Kettering Cancer Center), John N. Lukens(Merck Institute for Science Education), Susan Manber(Merck Institute for Science Education), Lawrence A. Mark(Merck Institute for Science Education), Theresa Medina(Merck Institute for Science Education), Kishwer S. Nehal(Memorial Sloan Kettering Cancer Center), Paul Nghiem(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kelly Olino(Yale Cancer Center), Soohyung Park(UC San Diego Health System), Tejesh Patel(University of Tennessee Health Science Center), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Jason T. Rich(Barnes-Jewish Hospital), Aleksander Sekulic(WinnMed), Ashok R. Shaha(Memorial Sloan Kettering Cancer Center), Divya Srivastava(Southwestern Medical Center), Valencia D. Thomas(The University of Texas MD Anderson Cancer Center), Courtney M. Tomblinson(Breast Cancer Research Foundation), Puja Venkat(Merck Institute for Science Education), Yaohui Xu(University of Wisconsin Carbone Cancer Center), Siegrid S. Yu(Merck Institute for Science Education), Mehran Yusuf(Merck Institute for Science Education), Beth McCullough(Merck Institute for Science Education), Sara Espinosa(Merck Institute for Science Education)
Journal of the National Comprehensive Cancer Network
January 1, 2024
10.6004/jnccn.2024.0002
Cited by 48Open Access
Full Text

Abstract

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC." This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical" by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.

Related Papers

No related papers found

Powered by citation graph analysis